Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis

Company Overview

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD. The company is conducting late-stage clinical trials to assess safety and efficacy in people who experience chronic pain and disrupted sleep due to these conditions. In addition to its CNS portfolio, Tonix is advancing live-virus vaccine candidates against orthopoxviruses, including those that could be used for smallpox or monkeypox, and is exploring development of vaccines against other biothreat agents.

Headquartered in New York, Tonix Pharmaceuticals leverages in-house research and collaborations with academic institutions and government agencies to advance its pipeline. The company was co-founded and is led by Seth H. Lederman, M.D., who serves as President and Chief Executive Officer. Under Dr. Lederman’s direction, Tonix continues to progress multiple programs through clinical development while maintaining a focus on unmet medical needs in both therapeutic and vaccine arenas.

Key Stats

• Today's Range: $12.73 to $13.49
• 50-Day Range: $12.03 to $16.08
• 52-Week Range: $11.60 to $69.97
• Volume: 146,062 shs
• Average Volume: 408,137 shs
• Market Capitalization: $177.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Hold

Tonix Pharmaceuticals Stock Analysis - MarketRank™

Tonix Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 198th out of 854 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Tonix Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Tonix Pharmaceuticals has a consensus price target of $22.00, representing about 71.7% upside from its current price of $12.81.

Amount of Analyst Coverage

Tonix Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($8.74) to ($4.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tonix Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tonix Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tonix Pharmaceuticals has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TNXP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tonix Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tonix Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.14

News Sentiment

Tonix Pharmaceuticals has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 21 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

11 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $223,350.00 in company stock, which represents 0.1301% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $223,350.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.00% of the stock of Tonix Pharmaceuticals is held by insiders.

Percentage Held by Institutions

82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNXP Stock Analysis - Frequently Asked Questions

How have TNXP shares performed this year?

Tonix Pharmaceuticals' stock was trading at $15.62 at the beginning of 2026. Since then, TNXP stock has decreased by 18.0% and is now trading at $12.8110.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its quarterly earnings results on Thursday, March, 12th. The company reported ($3.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.16) by $0.82. The business had revenue of $5.39 million for the quarter, compared to analyst estimates of $2.97 million. Tonix Pharmaceuticals had a negative trailing twelve-month return on equity of 60.15% and a negative net margin of 946.22%.

When did Tonix Pharmaceuticals' stock split?

Tonix Pharmaceuticals's stock reverse split on the morning of Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Tonix Pharmaceuticals' major shareholders?

Top institutional shareholders of Tonix Pharmaceuticals include SJS Investment Consulting Inc. (0.07%). Insiders that own company stock include Seth Lederman and Carolyn E Taylor.
View institutional ownership trends.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNXP
• CIK: 1430306
• Web: www.tonixpharma.com
• Phone: (862) 799-8599
• Fax: 212-923-5700
• Employees: 50
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Tonix Pharmaceuticals: $22.00
• High Price Target: $22.00
• Low Price Target: $22.00
• Potential Upside/Downside: +66.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$124.02 million
• Net Margins: -946.22%
• Pretax Margin: -946.22%
• Return on Equity: -60.15%
• Return on Assets: -54.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.42
• Quick Ratio: 7.23

Sales & Book Value

• Annual Sales: $13.11 million
• Price / Sales: 13.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $19.17 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 13,400,000
• Free Float: 13,137,000
• Market Cap: $177.62 million
• Optionable: Not Optionable
• Beta: 1.68